Hyperion Defi, Inc. · NASDAQ:HYPD
Hyperion Defi — Eyenovia — Corporate Update (February 2023)
6 slides from Hyperion Defi's corporate update, Feb 15, 2023
Slide 1: Formosa – Eyenovia Collaboration
Formosa – Eyenovia Collaboration
Slide 2: Formosa Pharmaceuticals
• Publicly traded (6838.TWO) Taiwanese clinical stage biotechnology company – Market cap $200M – Ophthalmology and oncology (biosimilars) focus • In topical eye care, Formosa’s proprietary nanoparticle formulation technology improves the dissolution and bioavailability of drugs – Drugs used in suspe
Slide 3: Formosa Pipeline
Formosa Pipeline Product Indication Pre - Clin Clinical Trial and Regulatory Timing Phase 1 Phase 2 Phase 3 Reg APP13007 Inflammation and Pain After Ocular Surgery USA 202 3 CHINA A PP 13 0 02 Anterior Ocular Infections (Including: Bacterial Conjunctivitis, Keratitis, Blepharitis, Meibomian Gland Dy
Slide 4: APNT Technology
• APNT Œ (Active Pharmaceutical Nanoparticle Technology) works to reduce particle size leading to improved dissolution, bioavailability, and lowers the risk of contamination – Reduces particle size by using common salts and sugars as milling media which can remain a part of the final formulation – T
Slide 5: Synergistic Technology
• Formosa’s APNT Œ technology can adjust the particle size of formulations increasing the probability of success with the Optejet ® Broadens the Optejet’s usability to existing suspension and emulsion products with viscosities that currently make them incompatible • Ophthalmic suspensions and emulsi
Slide 6: Collaboration Agreement
• Eyenovia and Formosa Pharmaceuticals have agreed to a collaborate in the development of an APNT Œ formulation to be dispensed using the Optejet ® • In 2023, Eyenovia will conduct feasibility testing of novel APNT Œ formulations in the Optejet and request a pre - IND meeting with the FDA • Formosa